Navigation Links
Experts tackle shipment issues for beneficial radiation sources
Date:5/16/2008

able manner.

The participants also stressed that successful communication and strong cooperation between a range of partners is essential for eventually resolving problems. Partners include the International Steering Committee on Denial of Shipments, the IAEA, the UN and International Modal Organizations, trade associations, regional networks, and national focal points in each country will lead to a better understanding and, eventually, a resolution of this problem. The workshop was hosted by the Government of Italy through the National Agency for Environmental Protection and Technical Services (APAT).

At the workshop, the IAEAs Khammar Mrabit, Head of the Regulatory Infrastructure and Transport Safety Section, highlighted the importance of tackling the issue of denial of shipments of radioactive material, emphasizing the importance of international safety standards and practices.

"There has been no significant accident from transport of radioactive material over the past half century," he said. "Denial of shipments potentially increases the risks to safety and security. We should not let the issue of denial of shipments of radioactive material render ineffective the good work that has been done for over 50 years of establishing a strong safety record."

In his welcome remarks, Roberto Mezzanotte, Director of APATs Department of Nuclear, Technological and Industrial Risk, also emphasized the urgency of the problem. "The issue of denial of shipments is not just for specialists but affects the lives of millions of people around the world. The majority of the radioactive material shipped every day is used in hospitals for diagnostics and treatment of several illnesses," he said.

The three-day Regional Workshop on Denial of Shipment of Radioactive Material for Countries in the Mediterranean Basin was held in Rome, Italy, from 14-16 May. More than 80 participants from 15 countries of the Mediterranean Basin and eight int
'/>"/>

Contact: Giovanni Verlini
G.VERLINI@iaea.org
43-126-002-1281
International Atomic Energy Agency
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization
2. Sudden ecosystem flips imperil worlds poorest regions, say water experts
3. Experts prove the geochemical origin of part of the CO2 emissions in semiarid climates
4. Leading researchers and experts gather to discuss latest advancements in drug discovery
5. Internationally recognized experts presents a complete overview on hydroecology and ecohydrology
6. Experts from Stevens, Merck, publish joint paper, Biosynthetic Studies of Platensimycin
7. Agriculture experts meet in Beijing to examine impacts of food prices and climate change on farmers
8. Now is Africas turn for a green revolution, global experts say
9. Soil, conservation experts to reflect on Hurricane Katrina disaster
10. Less Arctic ice means higher risks, experts warn
11. Improving science, technology in Africa is aim as G-8, African, UN experts convene in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6